Can reduced-intensity allogeneic transplantation cure older adults with AML?

Best Practice and Research in Clinical Haematology

Volumn 20, Issue 1, 2007, Pages 85-90

  Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

graft versus leukemia response; myeloid malignancies; reduced intensity allogeneic transplantation

Indexed keywords

BUSULFAN; CANCER VACCINE; CD45 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; IDARUBICIN; MELPHALAN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMORBIDITY; GERIATRIC PATIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; AGE FACTORS; AGED; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; META-ANALYSIS; MIDDLE AGED; NEOPLASM, RESIDUAL; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR BURDEN;

EID: 33847263418     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.10.008     Document Type: Review

References (11)

1. Breems D.A., and Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. British Journal of Haematology 130 (2005) 825-833
2. Baron F., and Sandmaier B.M. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Current Opinion in Hematology 12 (2005) 435-443
3. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology 24 (2006) 444-453
4. de Lima M., Shahjahan M., Alamo A., et al. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with AML and MDS. Blood 104 (2004) 632a (abstract 2301)
5. Rodriguez R., Parker P., Nademanee A., et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplantation 33 (2004) 1123-1129
6. Godwin J.E., Kopecky K.J., Head D.R., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 91 (1998) 3607-3615
7. Leopold L.H., and Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leukemia & Lymphoma 43 (2002) 1715-1727
8. de Witte T., Oosterveld M., Span B., et al. Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. Reviews in Clinical and Experimental Hematology 6 (2002) 72-85
9. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
10. Pagel J.M., Appelbaum F., Sandmaier B.M., et al. 131I-Anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with Advanced Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS). Blood 106 (2005) 119a (abstract 397)
11. Mielcarek M., Storer B., Kahl C., et al. Nonmyeloablative and myeloablative hematopoietic cell transplantation for hematologic malignancies: outcomes with HLA-matched unrelated donors compared to HLA-identical sibling donors. Blood 106 (2005) 194a (abstract 658)